Stavudine: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Potential in HIV Infection

Drugs

Volumn 51, Issue 5, 1996, Pages 846-864

  Lea, Andrew P ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DRUG METABOLITE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS ENZYME; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BLOOD DISEASE; CLINICAL TRIAL; DRUG METABOLISM; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PERIPHERAL NEUROPATHY; PHOSPHORYLATION; REVIEW; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS RESISTANCE; WEIGHT GAIN;

ANIMALS; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; STAVUDINE;

EID: 0029870457     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00009     Document Type: Review

References (114)

1. Wilde MI, Langtry HD. Zidovudine: an update on its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46 (3): 515-78
2. Faulds D, Brogden RN. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44 (1): 94-116
3. Whittington R, Brogden RN. Zalcitabine: a review of ils pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992; 44 (4): 656-83
4. Baba M, Pauwels R, Herdewijn P, et al. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987 Jan 15; 142: 128-34
5. Evans LA, Levy JA. The heterogenicity and pathogenicity of HIV. In: Morrow WJW, Haigwood NL, editors. HIV Molecular Organization, Pathogenicity and Treatment. Elsevier Science Publishers, 1993: 30-73
6. Fauci AS. Immunopathogenesis of HIV infection. AIDS 1993; 6 (6): 655-62
7. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993; 57 (1): 183-289
8. Wei X, Ghosh SJ, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995 Jan 12; 373: 117-22
9. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995 Jan 12; 373: 123-6
10. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995 Jan 27; 267: 483-9
11. Short N. A fight to the death. Examination of the effect of three new drugs shows that the destruction of the immune system in AIDS reflects fulminant HIV production, which eventually overwhelms the immune system's prodigious powers of regeneration. Nat Medic 1995; 1 (2): 122-4
12. August EM, Birks EM, Prusoff WH. 3′-Deoxythymidin-2′-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol Pharmacol 1991 Feb; 39: 246-9
13. Domin BA, Mahoney WB, Zimmerman TP. 2′,3′-Dideoxythymidine permeation of the human erythrocyte membrane by nonfacilitated diffusion. Biochem Biophys Res Commun 1988; 154 (3): 825-31
14. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989 Apr 15; 264: 6127-33
15. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3′-azido-3′deoxythymidine and selective interaction of the 5′-monophosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986 Nov; 83: 8333-7
16. Huang P, Farquhar D, Plunkett W. Selective action of 2′,3′-didehydro-2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 1992 Feb 5; 267: 2817-22
17. Yarchoan JA, Mitsuya H, Myers CE, et al. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989 Sep 14; 321: 726-38
18. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992 Feb; 8: 119-34
19. Sandström E, Öberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (Pt 1). Drugs 1993 Apr; 45: 488-508
20. Riddler SA, Anderson RE, Mellors JW. Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T). Antiviral Res 1995 Jun; 27: 189-203
21. Inoue T, Tsushita K, Itoh T, et al. In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33 (4): 576-9
22. Balzarini J, Kang G-J, Dalal M, et al. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol Pharmacol 1987 Jul; 32: 162-7
23. Balzarini J, van Aerschot A, Herdewijn P, et al. 5-Chloro-substituted derivatives of 2′,3′-didehydro-2′,3′-dideoxyuridine, 3′-flu′ oro-2′,3′-dideoxyuridine as anti-HIV agents. Biochem Pharmacol 1989; 38 (6): 869-74
24. Hamamoto Y, Nakashima H, Matsui T, et al. Inhibitory effect of 2′,3′-dihydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob Agents Chemother 1987; 31 (6): 907-10
25. Lin T-S, Schinazi RF, Prusoff WH. Potent and selective in vitro activity of 3′deoxythymidin-2′-ene(3′-deoxy-28é, 3′didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol 1987; 36 (17): 2713-8
26. Mansuri MM, Starrett Jr JE, Ghazzouli I, et al. 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J Med Chem 1989 Feb; 32: 461-6
27. Mansuri MM, Hitchcock MJM, Buroker RA, et al. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immmunodeficiency virus. Antimicrob Agents Chemother 1990 Apr; 34: 637-41
28. + HeLa cells and a plaque assay in MT-4 cells. J Virol Methods 1990 Aug; 29: 197-208
29. Nakashima H, Pauwels R, Baba M, et al. Tetrazolium-based plaque assay tor HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds. J Virol Methods 1989 Dec; 26: 319-29
30. Palomino E, Meltsner BR, Kessel D, et al. Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders. J Med Chem 1990; 33: 258-63
31. Perno C-F, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989 Mar 1; 169: 933-51
32. Sergheraert C, Pierlot C, Tartar A, et al. Synthesis and anti-HIV evaluation of D4T and D4T 5′-monophosphate prodrugs. J Med Chem 1993 Apr 2; 36: 826-30
33. Sørensen AM, Nielsen C, Mathiesen LR, et al. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis 1993; 25: 365-71
34. Maddon PJ, Dalgleish AG, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333-48
35. Merrill DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency type 1 replication in vitro. J Infect Dis 1996; 173 (2): 355-64
36. Gao W-Y, Johns DG, Ahluwalia G, et al. Enhancement of the anti-HIV activity of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) by the thymidylate synthetase inhibitor FUdR : an anti-HIV strategy with a host-cell target [abstract]. AIDS Res Hum Retroviruses 1995 Aug; 7 Suppl. 1: S161
37. Zhu Z, Ho H-T, Hitchcock MJ, et al. Cellular pharmacology of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem Pharmacol 1990 May 1; 39: R15-9
38. Watson A, Wilburn W, Ho H-T, et al. The inhibition of HIV-1 proviral DNA synthesis in resting PBL by nucleosides [abstract no. WA1027]. VII International Conference on AIDS; 1991; Florence, Italy
39. Gao W-Y, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994 Apr 29; 269: 12633-8
40. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168-71
41. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989 Mar 31; 243: 1731-4
42. Schinazi R, Larder B, Mellors J. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1994; 2 (5): 72-5
43. Gao Q, Gu z, Salomon H, et al. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Arch Virol 1994; 136 (1-2): 111-22
44. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994 Nov; 10: 1479-88
45. Mellors JW, Dutschman GE, Im G-J, et al. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992; 41: 446-51
46. De Clereq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 1994; 47 (2): 155-69
47. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News 1995; 3 (1): 8-13
48. Johnson VA. Nucleoside reverse transcriptase inhibitors and resistance of humun immunodeficiency virus type 1. J Infect Dis 1995; 171 Suppl. 2: S140-149
49. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992 Aug 27; 327 (9): 581-7
50. D'Aquila R, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995 Mar 15; 122 (6): 401-8
51. 3. Ann Intern Med 1995 Oct 15; 123 (8): 561-71
52. Montaner JSG, Singer J, Schechter MT, et al. Clinical correlates of in vitro HIV-1 resistant to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 1993; 7: 189-96
53. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother 1994 Jun; 38: 1428-32
54. Gu Z, Gao Q, Fang H, et al. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994 Apr; 8 Suppl. 1: 166-9
55. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994 Nov; 170: 1157-64
56. Zhu Z, Hitchcock MJ, Sommadossi JP. Metabolism and DNA interaction of 2′,3′-didehydro-2′,3′-dideoxythymidine in human bone marrow cells. Mol Pharmacol 1991 Nov; 40: 838-45
57. Chen C-H, Vazquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991 May; 39: 625-8
58. Lewis W, Dalakos MC. Mitochondrial toxicity of antiviral drugs. Nat Medic 1995; 1 (5): 417-22
59. Faraj A, Fowler DA, Bridges EG, et al. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994 May; 38: 924-30
60. Sommadossi J-P, Zhu Z, Carlisle R, et al. Pharmacologic studies of nucleosides active against the human immunodeficiency virus. Ann N Y Acad Sci 1990; 616: 356-66
61. Flint OP, Weiss A, Durham SK. Anti-AIDS nucleoside analogs (DDI, d4T, ddc, and AZT): comparative in vitro neurotoxicity study using the micromass culture technique. In Vitro Toxicol 1993; 6 (4): 221-41
62. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992 Sep; 166: 480-5
63. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39 (10): 2309-15
64. Kaul S, Mummaneni V, Barbhaiya RH. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations. Biopharm Drug Dispos 1995 Mar; 16: 125-36
65. Seifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994 Nov; 38: 405-10
66. Grasela D, Christofalo B, Raymond R, et al. Safety and pharmacokinetics (PK) of stavudine (d4T) in subjects with mild, moderate or severe renal impairment [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29: 145
67. Petty B, Grasela D, Schaad H, et al. Safety and pharmacokinetics (PK) of stavudine (d4T) in hepatic impairment [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan: 146
68. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995 Aug; 96 (Pt 1): 247-52
69. Kaul S, Dandekar DA, Barbhaiya RH, et al. Pharmacokinetics and oral bioavailability of D4T in patients with AIDS or ARC [abstract no. B90]. VIII International Conference on AIDS: 1992 Jul; Amsterdam, The Netherlands.
70. Dudley M, Geletko S, Graham KK, et al. Bioavailability of high-dose 2′,3′ didehydro-3′-deoxythymidine (d4T) in patients with HIV infection [abstract]. Pharmacotherapy 1991; 11 (3): 265
71. Macleod CM, Bartley EA, Paul SK, et al. Effect of food on oral absorption of stavudine [abstract]. J Clin Pharmacol 1994 Oct; 34: 1025
72. Kim GP, Brett-Smith H, Friedland G, et al. Anti-HIV effect, toxicity, and pharmacokinetics of 2′3′-didehydro-3′-deoxythymidine (D4T) at low/moderate doses [abstract]. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; 204
73. Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine (D4T) and didanosine (DDI) in children with advanced human immunodeficiency virus (HIV) infection [abstract]. Pediatric Academic Societies' Annual Meeting; 1996 May.
74. Zerit™(stavudine) capsules. Product Information Sheet, Bristol-Myers Squibb, Princeton, New Jersey, US, 1994 Jun.
75. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 1994; 38: 1-4
76. Odinecs A, Nosbisch C, Keller RD, et al. In vivo maternal-fetal pharmacokinetics of stavudine (2′,3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40 (1): 196-202
77. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994 May; 169: 1100-2
78. Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995 Jul; 29: 46-65
79. Matthes E, Lehmann C, Scholz D, et al. Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5-triphosphate in comparison to cellular DNA polymerases α and β. Biochem Biophys Res Commun 1987; 148 (1): 78-85
80. Ono K, Nakane H, Herdewijn P, et al. Differential inhibitory effects of several pyrimidine 2′,3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol Pharmacol 1989; 35: 578-83
81. Ho H-T, Hitchcock MJ. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989 Jun; 33: 844-9
82. Munch-Petersen B, Cloos L, Tyrsted G, et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991 May 15; 266: 9032-8
83. Martin JC, Hitchcock MJ, Fridland A, et al. Comparative studies of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues. Ann N Y Acad Sci 1990; 616: 22-8
84. Mars ME, Gensollen S, Ravaux L, et al. Association between AZT and d4T in HIV infected patients: a pilot study (comparison with d4T, AZT, and AZT + ddI) [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; 226.
85. Centers for Disease Control and Prevention. 1993 revised classification system tor HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 1-19
86. Cotton DJ, Powderly WG, Feinberg J, et al. Guidelines for the design and conduct of AIDS clinical trials. Clin Infect Dis 1993; 16: 816-22
87. Wolfe PR. Editorial response: Guidelines for AIDS clinical trials [editorial]. Clin Infect Dis 1993; 16: 823-4
88. Centers for Disease Control and Prevention. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep 1987; 36 (15): 225-35
89. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43 (12): 1-10
90. Centers for Disease Control and Prevention. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986; 35: 334-9
91. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36: 1-15s
92. Murray HW, Squires KK, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis 1995 Mar; 171 Suppl. 2: 123-30
93. Browne MJ, Mayer KH, Chafee SBD, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993 Jan; 167: 21-9
94. Katlama C, Molina JM, Rozenbaum W, et al. Stavudine (D4T) in HIV infected patients with CD4> 350/mm3: results of a double-blind randomised placebo controlled study [abstract no. 196]. Third Conference on Retroviruses and Opportunistic Infections, Washington DC; 1996 Jan
95. Calvez V, Fauveau V, Ferchal P, et al. Virological efficacy of stavudine vs placebo in early HIV infection [abstract]. Third Conference on Retroviruses and Opportunistic Infections, Washington DC, 1996 Jan
96. Kline MW, Dunkle LM, Federici ME, et al. Safety and preliminary virologic and immunologic efficacy of stavudine (d4T) in children with HIV infection [abstract]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995, 292
97. Gottlieb M, Peterson D, Adler M, et al. Comparison of safety and efficacy of two doses of stavudine (Zerit, d4T) in a large simple trial in the US Parallel Track Program [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1945; 235
98. Anderson RE, Dunkle LM, Smaldone L, et al. Design and implementation of the stavudine parallel-track program. J Infect Dis 1995 Mar; 171 Suppl. 2: 118-22
99. Petersen EA, Ramírez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995 Mar; 171 Suppl. 2: 131-9
100. Pavia AT, Gathe J, BMS-019 Study Group Investigators, et al. Clinical efficacy of stavudine (d4T, Zerit®) compared to zidovudine (ZDV, Retrovir®) in ZDV-pretreated HIV positive patients [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; 235
101. Stavudine (Zerit®), also known as d4T. Final results of the study BMS-019 (AI455-019) Phase III comparative trial. Bristol-Myers Squibb Company, Princeton, New Jersey, USA, 1995.
102. Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (d4T) and didanosine ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial [abstract]. Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan; Washington DC
103. Data on file (1996). Bristol-Myers Squibb, Princeton, New Jersey
104. Bristol-Meyers Zerit trial shows equivalence to AZT in AZT-experienced patients: advisory committee recommends narrow indication, traditional approval. FDC Rep Pink Sheet 1995 Nov 13: 19-20
105. Gorensek MJ, Widmayer SJ, Munger P et al. A study of D4T in children with HIV who failed or were intolerant of conventional therapy [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; 224
106. Federici ME, Dunkle L, Rutkiewicz V, et al. Safely profile of children on long-term therapy with Zerit® (stavudine, d4T) [abstract] 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; 252
107. World Health Organization. Statistics from the World Health Organization. AIDS 1995; 4: 1247-8
108. Hellinger FJ. Forecasts of the medical care costs of the HIV epidemic in the United States: 1992-1995. AIDS Lett 1992; 32 (Aug/Sep): 8
109. Emery S, Cooper DA. Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection. Aust N Z J Med 1995 Aug; 25: 344-9
110. Khoo SH, Wilkins EGL. Controversies in anti-retroviral therapy of adults. J Antimicrob Chemother 1995; 35: 245-62
111. Hirsch MS, Yeni P. A bend in the road - implications of ACTG 175 and Delta trials [editorial]. Antiviral Tlierapy 1996; 1 (1): 6-8
112. Data on file (1995). Bristol-Myers Squibb Co., Plainsboro, New Jersey
113. Eron JJ, Benoitt SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995 Dec 21; 333: 1662-9
114. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995; 171: 1166-71